CLNN Clene Inc.

NASDAQ
$3.77

Clene Inc. (CLNN) is confirmed to report earnings on November 4, 2026, before the market open. The consensus earnings estimate is a loss of $0.46 per share.

Clene Beat Consensus Estimates
Wednesday, November 4, 2026 · 8:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 4
Wednesday · 8:30 AM ET
Earnings Whisper
-
vs ($0.46)
Rev est $90K
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.91

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Clene Inc.

Clene, a clinical-stage biopharmaceutical company focused on neurodegenerative disease, is leading the way by using nanotechnology to treat bioenergetic failure, which underlies many neurological diseases.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.